Abstract
Alzheimer's disease (AD) is a neurodegenerative disease and one of the leading causes of progressive dementia, affecting 50 million people worldwide. Many pathogenic processes, including amyloid β aggregation, tau hyperphosphorylation, oxidative stress, neuronal death, and deterioration of the function of cholinergic neurons, are associated with its progression. The one-compound-one-target treatment paradigm was unsuccessful in treating AD due to the multifaceted nature of Alzheimer's disease. The recent develop-ment of multitarget-directed ligand research has been explored to target the complemen-tary pathways associated with the disease. We aimed to find the key role and progress of MTDLs in treating AD; thus, we searched for the past ten years of literature on “Pub-Med”, “ScienceDirect”, “ACS” and “Bentham Science” using the keywords neurodegen-erative diseases, Alzheimer’s disease, and multitarget-directed ligands. The literature was further filtered based on the quality of work and relevance to AD. Thus, this review high-lights the current advancement and advantages of multitarget-directed ligands over tradi-tional single-targeted drugs and recent progress in their development to treat AD.
Related Journals
Current Pharmaceutical Design
Current Topics in Medicinal Chemistry
Current Respiratory Medicine Reviews
Infectious Disorders - Drug Targets
Endocrine, Metabolic & Immune Disorders - Drug Targets
Anti-Infective Agents
Coronaviruses
Recent Advances in Inflammation & Allergy Drug Discovery
Current Probiotics
